Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30631773 | 1.00 | TDP1 (0.68) | TDP1RXRA | |
| SCHEMBL4447832 | 0.88 | TDP1 (0.74) | TDP1RXRA | |
| SCHEMBL19490488 | 0.85 | TDP1 (0.51) | TDP1RXRA | |
| SCHEMBL26843469 | 0.85 | TDP1 (0.75) | TDP1RXRA | |
| SCHEMBL16312041 | 0.84 | TDP1 (0.78) | TDP1RXRA | |
| SCHEMBL16312049 | 0.84 | TDP1 (0.70) | TDP1RXRA | |
| SCHEMBL2604424 | 0.84 | TDP1 (0.83) | TDP1RXRA | |
| SCHEMBL20944796 | 0.84 | TDP1 (0.76) | TDP1RXRA | |
| SCHEMBL16706991 | 0.83 | RXRA (0.71) | TDP1RXRA | |
| SCHEMBL16312037 | 0.83 | RXRA (0.71) | TDP1RXRA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3480187-B1 | METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES | UNIV NAT TAIWAN NORMAL (TW) | 2023-10-04 | — | — | EP | disclosed |
| US-20230204593-A1 | MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS | PIOMA, INC. | 2023-06-29 | — | — | US | disclosed |
| US-11513125-B2 | Microvesicle histone H2AX as a biomarker for genotoxic stress | PIOMA, INC. (US) | 2022-11-29 | — | — | US | disclosed |
| US-10336704-B2 | Method for preparing indenoisoquinoline derivatives | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-07-02 | — | — | US | disclosed |
| EP-3480187-A1 | METHOD FOR PREPARING INDENOISOQUINOLINE DERIVATIVES | National Taiwan Normal University (TW) | 2019-05-08 | — | — | EP | disclosed |
| US-20190127330-A1 | Method for Preparing Indenoisoquinoline Derivatives | NATIONAL TAIWAN NORMAL UNIVERSITY (TW) | 2019-05-02 | — | — | US | disclosed |
| EP-2971282-B1 | MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS | PIOMA INC (US) | 2018-09-19 | — | — | EP | disclosed |
| US-9402842-B2 | Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (Tdp1)—topoisomerase I (Top1) inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2016-08-02 | — | — | US | disclosed |
| US-20160081999-A1 | SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (Tdp1) - TOPOISOMERASE I (Top1) INHIBITORS | PURDUE RESEARCH FOUNDATION (US) | 2016-03-24 | — | — | US | disclosed |
| US-20160041175-A1 | MICROVESICLE HISTONE H2AX AS A BIOMARKER FOR GENOTOXIC STRESS | PIOMA, INC. | 2016-02-11 | — | — | US | disclosed |
| US-9175002-B2 | Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (Tdp1)—topoisomerase I (Top1) inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2015-11-03 | — | — | US | disclosed |
| US-20150133445-A1 | SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (Tdp1) - TOPOISOMERASE I (Top1) INHIBITORS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-05-14 | — | — | US | disclosed |
| US-8912213-B2 | Synthesis and use of dual tyrosyl-DNA phosphodiesterase I (TDP1)- topoisomerase I (TOP1) inhibitors | PURDUE RESEARCH FOUNDATION (US) | 2014-12-16 | — | — | US | disclosed |
| EP-2050452-A1 | indenoisoquinolines as topoisomerase inhibitors I useful as antineoplastic agents | Purdue Research Foundation (US) | 2009-04-22 | — | — | EP | disclosed |
| US-6509344-B1 | A method for treating a patient having cancer, said method comprising the step of administering to the patient an effective amount of a compound according to claim 1, whereupon said patient is treated for cancer, and wherein the cancer is | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | 2003-01-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150133445-A1 | SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (Tdp1) - TOPOISOMERASE I (Top1) INHIBITORS | TDP1, TOP1, TDP2 | TDP1 1/4885RXRA 4353/4885 |
| US-20160081999-A1 | SYNTHESIS AND USE OF DUAL TYROSYL-DNA PHOSPHODIESTERASE I (Tdp1) - TOPOISOMERASE I (Top1) INHIBITORS | TDP1, TOP1, TDP2 | TDP1 1/4885RXRA 4353/4885 |
| US-10336704-B2 | Method for preparing indenoisoquinoline derivatives | CYP1A2, RECQL, RDX | TDP1 3167/4885RXRA 1260/4885 |
| US-20190127330-A1 | Method for Preparing Indenoisoquinoline Derivatives | CYP1A2, RECQL, RDX | TDP1 3167/4885RXRA 1260/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.